TeraRecon Launches AI-Driven Neuroimaging Platform

A new artificial intelligence (AI)-powered neuroimaging platform may offer adjunctive benefits for timely assessment and treatment decisions in neurovascular emergencies.

One of the benefits of TeraRecon Neuro is automated screening for challenging cases involving possible intracerebral hemorrhages (ICHs) and large vessel occlusions (LVOs), according to TeraRecon, the manufacturer of the platform.

The company said TeraRecon Neuro enables radiologists to modify the platform’s algorithm to optimize AI outputs. TeraRecon noted the TeraRecon Neuro platform, viewable on diagnostic desktop viewers and via a mobile app, also enhances the assessment of brain function with six customizable computed tomography (CT) perfusion maps.

“We believe the best use case scenario is not autonomous AI, but rather expert clinical supervision that is augmented by AI-driven insights. TeraRecon Neuro was designed to accommodate all care team members and workflows, while simultaneously maintaining standardization across the care continuum to ensure timely delivery of coordinated care for numerous neurovascular emergencies,” noted Dan McSweeney, the president of TeraRecon.